Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents

Chapel, Helen

doi:10.1046/j.1365-2249.1999.00000.x

Cited by 23 publications

(14 citation statements)

References 37 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concern about Creuztfeldt-Jacob disease (CJD) and its variant started in 1996-1997, and in some countries immunoglobulin containing plasma from a donor at risk of developing or who actually developed CJD was withdrawn. However, as yet, no evidence of human-to-human transmission has been observed [6,7].…”

Section: Introductionmentioning

confidence: 95%

A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin

Matamoros

Gracia

Hernández

et al. 2005

International Immunopharmacology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 95%

A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin

Matamoros

Gracia

Hernández

et al. 2005

International Immunopharmacology

View full text Add to dashboard Cite

“…81 Augmenting the humoral immune response with IVIG neutralises superantigens, 82 enhances GAS clearance, and is anti-inflammatory. 83 IVIG is prepared from pooling immunoglobulin from blood donors, and due to variant CJD in the 1990s, 84 its use is strictly controlled in the UK and elsewhere. Studies assessing IVIG in severe invasive GAS disease are limited.…”

Section: Intravenous Immunoglobulin and Hyperbaric Oxygenmentioning

confidence: 99%

Bromine, bear-claw scratch fasciotomies, and the Eagle effect: management of group A streptococcal necrotising fasciitis and its association with trauma

Lamb

Sriskandan

Tan

2015

The Lancet Infectious Diseases

View full text Add to dashboard Cite

“…Although there have been no reports of transmission of HIV, there were several outbreaks of hepatitis C in the mid-1990s. 20 Indeed, the manufacturer's datasheet still states that the risk of hepatitis C cannot be entirely excluded. The situation over potential transmission of Creutzfeldt-Jakob disease is less clear, although UK derived plasma is not now used for the production of immunoglobulin in the UK.…”

Section: Figurementioning

confidence: 99%

“…The situation over potential transmission of Creutzfeldt-Jakob disease is less clear, although UK derived plasma is not now used for the production of immunoglobulin in the UK. 20 Repeated intravenous access is required, although many of these patients do already have an implanted venous access device. It is time consuming for the children and their carers, requiring a night in hospital every month.…”

Section: Figurementioning

confidence: 99%

Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children

Balfour‐Lynn

Mohan²,

Bush³

et al. 2004

Archives of Disease in Childhood

View full text Add to dashboard Cite

Background and objective: Some children with severe cystic fibrosis (CF) lung disease develop chest tightness, recurrent dry cough, and intractable wheeze, often accompanied by deteriorating lung function and failure to expectorate sputum. In an attempt to reduce the use of regular oral corticosteroids, we treated a group of such children with monthly courses of intravenous immunoglobulin (IVIG). Methods: This is a retrospective case note review of 16 children, aged 3-16 years (median 13.0 years) who received 1-66 (median 7.5) courses of monthly IVIG, at a dose of 1 g/kg on two successive days for the first dose, followed by 1 g/kg monthly as a 12 hour infusion, with corticosteroid and antihistamine cover. Results: FEV 1 improved from a median (95% confidence interval (CI)) of 50% (39 to 61%) to 54% (48 to 66%), with a median (95% CI) difference of +7.5% (21.5 to 14.5%; NS). FVC improved from 65% (60 to 77%) to 83% (70 to 89%), with a difference of +13% (4 to 22%, p = 0.01). The total daily dose/kg body weight of oral prednisolone was reduced from 0.6 (0.3 to 1.0) to 0 (0 to 0.1) mg/kg/day, with a reduction of 20.6 (21.0 to 20.1, p = 0.006) mg/kg/day. The total daily dose of inhaled corticosteroid (budesonide equivalent) was a median (range) of 2000 mg (800-6000 mg), which was reduced to 1500 mg (0-3200 mg). The median (95% CI) difference was 2400 mg (21600 to 0 mg), p,0.05. IVIG was well tolerated and the regimen acceptable to all but one of the children. The following transient adverse reactions were seen in only one patient each: headache, fever, hypotension, aseptic meningitis, and chest tightness. Conclusion: We suggest that an n = 1 trial of IVIG in carefully selected patients with severe obstructive CF lung disease is worth considering, as for some it may lead to significant benefit.

show abstract

Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents

Cited by 23 publications

References 37 publications

A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin

A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin

Bromine, bear-claw scratch fasciotomies, and the Eagle effect: management of group A streptococcal necrotising fasciitis and its association with trauma

Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children

Contact Info

Product

Resources

About